PTC Therapeutics Inc(PTCT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 29 at 4:21 PM ET (Korea 10/30 05:21)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.59 | Insider Own | 3.11% | Shs Outstand | 83.3M | Perf Week | 2.25% |
| Market Cap | 5.38B | Forward P/E | 26.4 | EPS next Y | 113.19% | Insider Trans | -11.11% | Shs Float | 80.9M | Perf Month | -0.49% |
| Enterprise Value | 3.85B | PEG | - | EPS next Q | 0.28 | Inst Own | 121.02% | Short Float | 10.27% | Perf Quarter | -5.22% |
| Income | -0.04B | P/S | 5.33 | EPS this Y | -85.28% | Inst Trans | 7.43% | Short Ratio | 7.59 | Perf Half Y | -0.92% |
| Sales | 1.01B | P/B | - | EPS next 5Y | -20.14% | ROA | -1.3% | Short Interest | 8.30M | Perf YTD | -15.14% |
| Book/sh | -1.98 | P/C | 2.41 | EPS past 3/5Y | - | ROE | - | 52W High | -29.06% ($90.87) | Perf Year | -4.29% |
| Cash/sh | 26.71 | P/FCF | - | Sales past 3/5Y | 35.3% 35.37% | ROIC | -8.39% | 52W Low | 9.63% ($58.80) | Perf 3Y | 248.24% |
| Dividend Est. | - | EV/EBITDA | 22.36 | EPS Y/Y TTM | -106.21% | Gross Margin | 89% | Volatility(W/M) | 3.61% 3.4% | Perf 5Y | 69.94% |
| Dividend TTM | - | EV/Sales | 3.81 | Sales Y/Y TTM | -42.84% | Oper. Margin | 11.57% | ATR (14) | 2.14 | Perf 10Y | 908.76% |
| Dividend Ex-Date | - | Quick Ratio | 3.28 | EPS Q/Q | 210.6% | Profit Margin | -3.8% | RSI (14) | 53.72 | Recom | 1.76 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.39 | Sales Q/Q | 101.55% | SMA20 | 3.52% ($62.27) | Beta | 0.5 | Target Price | $97.81 |
| Payout | - | Debt/Eq | - | Earnings | 2026/10/29 | SMA50 | -1.7% ($65.57) | Rel Volume | 1.39 | Prev Close | $63.02 |
| Employees | 991 | LT Debt/Eq | - | EPS/Sales Surpr. | -533.26% 16.77% | SMA200 | -8.9% ($70.76) | Avg Volume(3M) | 1.09M | Price | $64.46 |
| IPO | 2013/6/20 | Option/Short | Yes/Yes | Trades | 16312 | Volume | 1,524,099 | Change | 2.28% |
🧬 This is a commercial-stage biotech company that develops and markets treatments for rare diseases. It sells therapies for conditions such as muscular dystrophy and metabolic disorders, earns royalty revenue through partnerships, and maintains a diverse pipeline. As a healthcare stock, its earnings and valuation are closely tied to sales of its key therapies, royalty income, and progress in clinical development.
Over the past 1 year, on the lower side
29% below its 1-year high.
Traded more than usual. That is 139% of its average volume.
PTCT keeps an operating profit but posts a net loss
Of every $100 in sales, $11.57 is kept as operating profit.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by -85.3% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $533. Peers typically go for $1,632. Compared with its own 1-year average, it is 13% pricier now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +69.9%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 121.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #50 of 594 in the industry
Based on market cap of $5B.
COGT#48 Cogent Biosciences Inc $6B PER - 
SRRK#49 Scholar Rock Holding Corp $5B PER - PTCT#50 PTC Therapeutics Inc $5B PER - 
CRSP#51 CRISPR Therapeutics AG $5B PER - 
ERAS#52 Erasca Inc $5B PER - 
FAQ
What kind of company is PTCT?
PTCT belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of PTCT?
The market cap of PTCT is approximately $5.4B, ranking 1,332 within its sector.
What is the 52-week high and low for PTCT?
PTCT has recorded a 52-week high of $90.87 and a low of $58.80.
